The project leverages blockchain and related technologies to make clinical trial processes tamper-resistant, and to enable secure and compliant connections between the many isolated systems and parties involved in clinical research.
Triall was founded back in 2018 and has since developed and commercialized its first product Verial eTMF, a blockchain-integrated document management application that enables clinical researchers to generate verifiable proofs of the existence, integrity, and authenticity of essential clinical trial documents.
Next to Verial eTMF, Triall will release several complementary, industry-validated applications that are all designed to support clinical trial professionals in their day-to-day operations. Moreover, the project is offering APIs that enable existing third-party clinical trial software providers to connect to Triall’s blockchain infrastructure. This provides them and their users a gateway to blockchain functionalities, and enables secure and compliant integrations with other applications in the Triall ecosystem.
Triall’s native TRL token enables access to ecosystem utilities, P2P compensation, governance, and community engagement.
As of Apr 4, 2026, Triall trades at $0.00253.
Triall has a market capitalization of $107,342.98.
Triall has a 24-hour trading volume of $23.09.
Triall has decreased by 0.24% over the last hour.
Triall has decreased by 0.24% over the last 24 hours.
Triall has decreased by 0.24% over the last 7 days.
Triall is currently —.
Triall is currently —.
Triall has a circulating supply of 42,365,415.44.
Triall has a total supply of 172,159,214.
Triall has a fully diluted valuation of $436,206.82.
All images, branding and wording is copyright of Triall. All content on this page is used for informational purposes only. CryptoSlate has no affiliation or relationship with the coins, projects or people mentioned on this page. Data is provided by CoinMarketCap and TradingView.
